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Abstract Toﬁsopam is a member of the 2,3-benzodiaz-
epine compound family which is marketed for the treat-
ment of anxiety in some European countries. In contrast to
classical 1,4-benzodiazepines, the compound does not bind
to the benzodiazepine binding site of the c-aminobutyric
acid receptor and its psychopharmacological proﬁle differs
from such compounds. In addition to anxiolytic properties,
antipsychotic effects are reported. We now show that tof-
isopam, 50 mg/kg intraperitoneally (i.p.), administered in
parallel to repeated doses of dizocilpine 0.2 mg/kg i.p. can
ameliorate dizocilpine-induced prolongation of immobility,
which is considered to be a model of negative symptoms of
psychosis. We further show that toﬁsopam acts as an iso-
enzyme-selective inhibitor of phosphodiesterases (PDEs)
with highest afﬁnity to PDE-4A1 (0.42 lM) followed by
PDE-10A1 (0.92 lM), PDE-3 (1.98 lM) and PDE-2A3
(2.11 lM). The data indicate that toﬁsopam is an inter-
esting candidate for the adjuvant treatment of psychosis
with focus on negative symptoms. Combined partial inhi-
bition of PDE-4 and PDE-10 as well as PDE-2 may be the
underlying mechanism to this activity. Due to the good
safety proﬁle of toﬁsopam as evident from long-term use of
this agent in patients, it may be concluded that dual or
triple inhibition of PDE isoenzymes with additive or syn-
ergistic effects may be an interesting approach to phar-
macological activity, resulting in active compounds with
beneﬁcial safety proﬁle. Dose-limiting side effects such as
emesis induced by selective inhibition of PDE-4 may be
prevented by such strategies.
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Introduction
Toﬁsopam, a 2,3-benzodiazepine (2,3-BDZs), represent a
unique drug among CNS-active compounds. Though sharing
a common chemical backbone to ‘classical’ 1,4-benzodiaze-
pines and though sharing the anxiolytic activity, the com-
pound does not interact with the benzodiazepine binding site
ofthec-aminobutyricacid(GABA)receptor(Petocz1993).It
isananxiolytic without sedative–hypnoticormusclerelaxant
effects. Toﬁsopam does not impair psychomotor and intel-
lectual performance, like other benzodiazepines do. In con-
trast, it has a mild cognitive stimulatory activity. It is also
potent in alleviating vegetative symptoms accompanying
anxiety disorders (Szeg} oe ta l .1993). Toﬁsopam does not
possess anticonvulsive properties and does not induce sleep
eveninsubtoxicdoses,andonlysuchsubtoxicdosesenhance
the effect of barbiturates and ethanol. Applying doses above
200 mg/kg to experimental animals, toﬁsopam exhibits
effects similar to that of neuroleptics (e.g., catalepsy, ptosis,
decrease of pentylenetetrazole threshold, potentiation of
amphetamine-andapomorphine-induced stereotypy) (Petocz
1993). This unique pharmacological proﬁle lead to the con-
clusion that toﬁsopam may be of interest for treatment of
psychosis. Current antipsychotics are well capable of ame-
liorating the positive symptoms of a psychotic episode. If
administered chronically, the re-occurrence of such an
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treatment with classical antipsychotic is hampered with side
effectsandpatientcomplianceforlong-termtreatmentisoften
low, potentially due to these side effects. Some of the side
effects of such classical antipsychotics overlap with the neg-
ative symptoms of psychosis, i.e., the compounds exert neg-
ative effects on attention, concentration, cognition and
memory (Arnt and Skarsfeldt 1998).
While some 2,3-BDZs and in part also toﬁsopam have
been shown to induce antipsychotic-like effects in classical
animal models of psychosis linked to the positive symptoms
of the disease, i.e., in the apomorphine climbing test, the
conditioned avoidance reaction and—to a lesser extent—in
the catalepsy test, the pharmacological proﬁle and the side
effect proﬁle of toﬁsopam in man differs from classical an-
tipsychotics (Horva ´th et al. 2000). Due to the reported mild
stimulatoryactivity(Szeg} oetal.1993)whichisincontrastto
the activity of classical antipsychotics we were interested to
see whether toﬁsopam may be active in a model of negative
symptoms of psychosis, which mimics the state of avolition.
ArespectivemodelhasbeendescribedbyNodaetal.(1995).
Due to the interesting pharmacological proﬁle of toﬁso-
pam we were also interested to learn more about the mech-
anism of action. Early binding studies identiﬁed speciﬁc and
exclusive binding of 2,3-BDZs within the striatum and
associated structures (Horva ´th et al. 2000). The binding site
was named girisopam binding site, since this 2,3-BDZ
derivative was found to have the highest afﬁnity. The dis-
tribution of this proposed binding site overlaps largely with
the distribution of the phosphodiesterase 10 isoenzyme
(PDE-10), which is highly and selectively expressed in
striatum (Seeger et al. 2003). Furthermore, PDE-10 inhibi-
tors are discussed to be interesting targets for antipsychotic
agents (Siuciak et al. 2006). Horva ´th et al. (2000) proposed
that the mechanism of action of toﬁsopam may be related to
alteration in the phosphorylation of protein(s). While inhi-
bitionofphosphodiesterasedoesnotdirectlyresultinprotein
phosphorylation, the second messengers—cyclic adenosine
monophosphate (cAMP) or cyclic guanosine monophos-
phate (cGMP)—which are cleaved by phosphodiesterases,
can activate protein kinases resulting in increased protein
phosphorylation. For these reasons we screened different
PDE isoenzymes including PDE-10 for speciﬁc interaction
with toﬁsopam.
Materials and methods
Phosphodiesterase screen
To screen for interaction with different PDE isoenzymes,
toﬁsopam was analyzed using the IMAP Technology
(Molecular Devices Inc., Sunnyvale, CA, USA), as
established at Scottish Biomedical, Glasgow, UK. In brief,
the assay is based on the high-afﬁnity binding of phosphate
by immobilized metal coordination complexes on nano-
particles. The binding reagent complexes with phosphate
groups on nucleotide monophosphate generated from cyc-
lic nucleotides (cAMP/cGMP) through phosphodiesterases.
With ﬂuorescence polarization detection, binding causes a
change in the rate of the molecular motion of the phos-
phate-bearing molecule and results in an increase in the
ﬂuorescence polarization value observed for the ﬂuorescent
label attached to the substrate. Using human recombinant
protein of PDE-1A3, PDE-2A3, PDE-3A, PDE-4A1, PDE-
5 (catalytic domain only), PDE-6C, PDE-8A1, PDE-9A1,
PDE-10A1 and PDE-11A1, selective inhibition of different
isoenzymes was screened using a single-point assay at a
concentration of 10,000 nM. The assays have been vali-
dated using reference PDE inhibitors (MacKenzie et al.
2010). Toﬁsopam was dissolved in DMSO and diluted in
assay buffer, ﬁnal DMSO concentration 0.1%. Reactions
were carried out in duplicate. For isoenzymes where the
single-point analysis resulted in an inhibition[50%, IC50
was determined using the same method but with an 8-point
assay, using 3 parallel experiments for each isoenzyme.
The IC50 determination was conducted for PDE-2A3, PDE-
3A, PDE-4A1 and PDE-10A1.
Animals
The animal experiments were carried out on a total of 49
male Albino Swiss mice weighing 25–30 g purchased from
the licensed breeder (Laboratory Animals Breeding,
Go ´rzkowska, Warsaw, Poland). They were used in this
study after at least 1 week of acclimatization. The animals
were housed in polycarbonate cages in groups of 6–10
under the strictly controlled laboratory conditions (ambient
temperature 22–23C, relative humidity about 45–55%,
12/12 light/dark cycle, light on at 6:00 h; chow pellets and
tap water continuously available). The experimental pro-
tocol was approved by the Local Ethics Committee at the
Medical University of Lublin (license no. 18/2007), and all
the procedures were in strict compliance with the European
Communities Council Directive of 24 November 1986 (86/
609/EEC).
Drugs
Toﬁsopam [1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dime-
thoxy-4-methyl-5H-2,3-benzodiazepine, racemic mixture,
kindly provided by EGIS Pharmaceuticals PLC (Budapest,
Hungary)], was freshly suspended in a 0.5% aqueous
solution of methyl cellulose (Sigma, St. Louis, MO,
USA) and administered intraperitoneally (i.p.) at a vol-
ume of 5 ml/kg. Dizocilpine [(?)-5-methyl-10,11-dihydro-
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801; purchased from Sigma] was dissolved extempore in
physiological saline and administered i.p. at a volume of
5 ml/kg. Control animals received respective vehicles at
appropriate volumes.
Forced swimming test in mice chronically treated
with dizocilpine
Acute administration of the potent N-methyl-D-aspartate
(NMDA) receptor antagonist phencyclidine can induce
both, positive and negative symptoms of psychosis in
man and exacerbates psychosis in schizophrenic patients
(Abdel-Naby et al. 2001). In animals, phencyclidine can
induce a wide range of abnormal behaviors which may be
linked to psychotic behavior. Upon repeated administration
of phencyclidine, a state of avolition can be induced in
mice, which persists for several days after termination
of treatment with phencyclidine. Avolition is one of the
negative symptoms of schizophrenia; it is quantiﬁed in a
forced swim test and animals exhibit a state of prolonged
immobility as indicator of avolition (Abdel-Naby et al.
2001). This model was proposed to be an ideal model of
negative symptoms of psychosis (Noda et al. 1995), it is
however limited to the depressive component and may not
be useful to model other negative symptoms such as
learning and memory deﬁcits or social retract.
Since phencyclidine is a controlled substance, we have
re-established the model using the NMDA-receptor
antagonist dizocilpine instead. The forced swim test and
the drug treatment protocol were carried out on mice
essentially as described by Noda et al. (1995). The dose of
dizocilpine and the treatment schedule was selected based
on preliminary experiments (data not presented). On the
ﬁrst day (Friday), each animal was placed individually into
a glass cylinder (height 20 cm, diameter 15 cm) containing
11 cm of water maintained at 23C, and was forced to
swim for 3 min, and the immobility time was recorded
(ﬁrst measurement of immobility as baseline measure-
ment). The mouse was judged to be immobile when it
remained ﬂoating passively in the water. For induction of
avolition, mice were chronically treated with 0.2 mg/kg
dizocilpine i.p. daily excluding weekends starting on the
fourth day (Monday) after the ﬁrst swim test, until day
19 (Friday). After a 2-day drug-free period, on the 22nd
day (Monday), each mouse was placed in water again
for 3 min, and the immobility was recorded to test for
prolongation of immobility (second measurement of
immobility).
For the current experiment, a group of 49 mice was
exposed to an initial swim test to determine the individual
immobility time. The mice were thereafter randomized to
three treatment groups of 16–17 mice. Three days after this
baseline swim test, treatment was initiated. One group
received the vehicle of dizocilpine and vehicle of toﬁsopam
(vehicle control group); the second group received treat-
ment with dizocilpine 0.2 mg/kg once daily plus toﬁso-
pam-vehicle twice daily on 5 days per week (psychosis
control), and a third group dizocilpine 0.2 mg/kg once
daily plus toﬁsopam 50 mg/kg twice daily on 5 days per
week until experimental day 19. The treatment schedule
consisted of two administrations of toﬁsopam at a dose of
50 mg/kg i.p. each, given 4 h apart. The ﬁrst dose was
given 10 min before the daily dizocilpine dose. The 4-h
break between two toﬁsopam administrations was selected
based on the rapid absorption and short half-life of tof-
isopam (Klebovich and Abermann 1993) to safely cover
the duration of action of dizocilpine. After a washout of
2 days, a second quantiﬁcation of immobility was con-
ducted on day 22, about 72 h after the last dizocilpine dose
and 68 h after the last toﬁsopam dose. This washout period
was selected to ensure that animals are free of both, tof-
isopam and dizocilpine plasma levels. The half-life of
dizocilpine in rodents is reported to be in the range of 2 h
(Vezzani et al. 1989).
Statistical analysis
All data are presented as means ± standard error of the
mean (SEM), where appropriate. Statistical analysis of the
effect of toﬁsopam on the prolonged immobility after
termination of treatment was performed by one-way
analysis of variance (ANOVA) of the individual differ-
ences between the two measurements of immobility fol-
lowed by Tukey’s post hoc test. The use of individual
differences results in a baseline adjustment. A p value less
than or equal to 0.05 was considered statistically
signiﬁcant.
To test for effects of repeated determination of immo-
bility in the same group, individual groups were also
compared using paired t test.
Results
Phosphodiesterase screen (Table 1)
Toﬁsopam was found to act as low-afﬁnity blocker of a
numberofPDEisoenzymes.Whilenointeractionwasfound
with PDE-6, PDE-8, PDE-9, and PDE-11, weak inhibition
was identiﬁed for PDE-1 and PDE-5. Due to an inhibition of
less than 50% measured at 10,000 lM, no IC50 was deter-
mined for these isoenzymes. Inhibition in the high nano-
molar to low micromolar range was found for PDE-2A3
(2.11 ± 1.8 lM), PDE-3A (1.98 ± 1.7 lM), PDE-4A1
(0.42 ± 0.8 lM), and PDE-10A1 (0.92 ± 1.2 lM).
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of psychosis (Fig. 1)
The animals of all three treatment groups had similar
immobility times at the pre-test. In addition, the immo-
bility time of vehicle-treated animals was compared
between the pre-test and the second measurement on day
22 and the immobility time was similar for both assess-
ments, with 95.2 s at the ﬁrst measurement and 103.2 at
the second measurement (not signiﬁcant, paired t test),
indicating that repeated measurement of immobility had
no effect on immobility time. As expected, animals which
had received repeated doses of dizocilpine showed a
signiﬁcant prolongation of the immobility time, with
92.0 s at the ﬁrst test and 128.2 s at the second test. This
difference was highly signiﬁcant (p\0.001, paired t test)
and the data indicate that the model could be established
successfully.
To evaluate the effect of subchronic treatment of tof-
isopam on the avolition representing as prolonged immo-
bility induced by repeated administration of dizocilpine,
the individual differences of the immobility times deter-
mined during the ﬁrst measurement on day 1 and second
measurement on day 22 were calculated and compared
using one-way analysis of variance (ANOVA). It became
evident that treatment with toﬁsopam in parallel to treat-
ment with dizocilpine ameliorated the prolonged immo-
bility time. The immobility of this group amounted to
117 s and was not signiﬁcantly different from the vehicle
control group. In contrast, the immobility of the mice
treated with dizocilpine was signiﬁcantly prolonged
[ANOVA on individual differences: F(2, 46) = 6.005,
p = 0.0048; Tukey’s post hoc test: p\0.004].
Discussion
Toﬁsopam isan atypical2,3-benzodiazepine whichdoesnot
bind to benzodiazepine receptors and which is devoid of
CNS side effects characteristic of 1,4-benzodiazepines. The
molecule has one chiral centre. Toﬁsopam was marketed in
the racemate form and it was orally administered at 300 mg/
day for its anxiolytic properties (Bernard et al. 2008).
The clinical success of toﬁsopam initiated further
chemical and pharmacological investigations resulting in
structurally related derivatives (La ´ng et al. 1985). Among
them, the most active compounds show beside their tran-
quilizing (anti-aggressive) character particular pharmaco-
logical properties reminiscent of both anxiolytics and
Table 1 Inhibition of phosphodiesterase (PDE) isoenzymes by
toﬁsopam
PDE isoenzyme % inhibition at 10,000 nM IC50 (lM)
PDE-1A3 37.8 n.d.
PDE-2A3 83.4 2.11 ± 1.8
PDE-3A 81.7 1.98 ± 1.7
PDE-4A1 92.1 0.42 ± 0.8
PDE-5 (catalytic domain) 42.0 n.d.
PDE-6C 5.3 n.d.
PDE-8A1 7.9 n.d.
PDE-9A1 2.8 n.d.
PDE-10A1 89.6 0.92 ± 1.2
PDE-11A1 4.2 n.d.
Effect of toﬁsopam (10,000 nM) on activity of different PDE isoen-
zymes, as determined using the IMAP Technology (Molecular
Devices, Inc., Sunnyvale, CA, USA). Percent inhibition values were
determined from double determinations. For isoenzymes where the
inhibition exceeded 50%, IC50 values were determined with an
8-point assay, using 3 parallel experiments for each individual iso-
enzyme. IC50 values are given as means ± standard error of the mean
of 3 measurements
Fig. 1 Immobility of mice in the forces swim test prior to repeated
administration of dizocilpine (0.2 mg/kg i.p. once daily 5 days per
week) or dizocilpine plus toﬁsopam, 50 mg/kg i.p. twice daily, 5 days
per week (panel a) and on day 22, 3 days after cessation of drug
treatment (panel b). Immobility on day 1 was similar for all three
groups [ANOVA: F(2, 46) = 0.2696, not signiﬁcant]. On day 21
(panel b), immobility of the dizocilpine-treated mice was signiﬁcantly
increased if compared to the control group; ANOVA on individual
differences: F(2, 46) = 6.005, p = 0.0048. The immobility of the
toﬁsopam-treated group was not signiﬁcantly different from the
vehicle group. **p\0.004 versus respective control group (Tukey’s
post hoc test)
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123atypical neuroleptics (Andra ´si et al. 1987; Horva ´th et al.
1989).
The 2,3-BZDs toﬁsopam, nerisopam and girisopam were
shown to speciﬁcally bind to a binding site in the striatum
and related brain regions (Horva ´th et al. 1994). This
binding site was identiﬁed as girisopam binding site
(Horva ´th et al. 2000). The molecular correlate of that
binding site could however not be identiﬁed to date.
Compounds with afﬁnity to the binding site were found to
be active in models of anxiety including elevated maze,
lick conﬂict test, light–dark box, and anti-aggressive
behavior in ﬁghting mice and in models of psychosis, i.e.,
in the apomorphine climbing test, the conditioned avoid-
ance reaction and—only at high doses—in the catalepsy
test. The pattern of distribution of this binding site largely
overlaps with the distribution of the PDE-10 isoenzyme
(Seeger et al. 2003). PDE-10 was recently shown to be a
very interesting target for antipsychotic activity and drug
development programs are ongoing to identify novel PDE-
10 inhibitors (Schmidt et al. 2008).
We now show that toﬁsopam acts as an inhibitor of
phosphodiesterases with some selectivity for PDE 2, 3, 4
and 10 and afﬁnities in the range of 0.42–2.1 lM. Activity
of toﬁsopam as PDE inhibitor was reported previously,
supporting the ﬁndings of our study for PDE1 to PDE5
(Bernard et al. 2008). Recently, it could be also shown that
toﬁsopam blocks PDE-10A isoenzymes with an afﬁnity of
264 nM for the racemate without stereo-selectivity (Niel-
sen et al. 2007). The same group reported afﬁnity to the
PDE4D isoenzymes with afﬁnity of S(-)-toﬁsopam of
117 nM and R(?)-toﬁsopam of 1,257 nM.
Phosphodiesterases are widely distributed throughout
the body, and they serve diverse functions. While PDE-3 is
known to selectively affect cardiac contractility by
increasing the intracellular level of cyclic adenosine
monophosphate (Goenen 1989), the other three phospho-
diesterases targeted by toﬁsopam have potent CNS activity,
and more speciﬁcally are discussed to be useful for ame-
lioration of symptoms of psychosis. The oldest phospho-
diesterase target for treatment of symptoms of psychosis is
the PDE-4 isoenzyme. Rolipram, being the prototype PDE-
4 inhibitor, was shown to have not only antidepressant and
immune modulator, but also antipsychotic and cognitive
enhancing activity (Kanes et al. 2007). However, the
clinical utility of rolipram and other PDE-4 inhibitors is
hampered by the fact that these compounds induce emesis,
nausea and gastrointestinal side effect. Roﬂumilast is the
only selective potent PDE4 inhibitor which is submitted for
marketing approval for the treatment of chronic obstructive
pulmonary disease, albeit with a narrow margin of safety
(Field 2008). Roﬂumilast, however, is not published to be
active in behavioral models of CNS diseases and it is not
known whether roﬂumilast can penetrate the brain. The
compound has a plasma protein binding of 98.9% (Bethke
et al. 2007).
The discovery that PDE-10 is selectively expressed in
medium spiny neurons of the striatum and the correlation of
PDE-10 function with dopaminergic neurotransmission has
placed PDE-10 as a highly interesting novel target for
treatment of psychosis (Siuciak et al. 2006). PDE-10 inhib-
itors exhibit a broad spectrum of antipsychotic activity in
different animal models (Siuciak et al. 2006; Siuciak 2008;
Schmidt et al. 2008). Both, effects in models of positive and
negative symptoms are reported. The pharmacological
activity could be correlated not only to an inhibition of the
D2-receptor-dominatedpathways,butalsotoafacilitationof
the D1-receptor-dominated prefrontal pathways. This com-
binationofactivityisbelievedtobehighlyinterestingforthe
amelioration of negative symptoms of psychosis (Siuciak
2008). The target is subject to drug discovery programs, but
none of these programs has reached a state of proof of efﬁ-
cacy in patients (Verhoest et al. 2009).
The PDE-2 isoenzyme is a further candidate for the
treatment of symptoms of psychosis, however, with
focus on the memory impairment contributing to the neg-
ative symptoms of psychosis (Boess et al. 2004; Domek-
Łopacin ´skaandStrosznajder2008).Furthermore,anxiolytic
effects may be mediated by PDE-2 inhibition (Masood et al.
2009).
We now show that toﬁsopam acts as a mixed blocker of
all three psychosis treatment related targets. The afﬁnity of
toﬁsopam to these isoenzymes is in the same range or even
higher than the afﬁnity of rolipram which was found to
have an afﬁnity of 1.1 lM (Bernard et al. 2008). While
toﬁsopam remains to be a low-afﬁnity PDE inhibitor if
compared with modern PDE inhibitors, it is possible that
the pharmacological activity is mediated by its interaction
with some or all of these phosphodiesterase isoenzymes. In
volunteers administered a single dose of 100 mg toﬁsopam,
a maximal plasma level of 328.8 ng/ml was reached, equal
to about 0.9 lM. The apparent volume of distribution
ranged from 523.8 to 5,154.1 l
-1 indicating that toﬁsopam
has higher concentration in extravascular tissue than in the
vascular compartment. The half-life was found to be in the
range of 4 h, indicating that upon three times daily
administration of 100 mg some accumulation can be
expected (To ´th et al. 2006). These data indicate that the
steady-state tissue concentration can be expected to be in
the range of or even higher than the IC50 of PDE-4, PDE-
10, and potentially also PDE-2 resulting in a partial block
of these enzymes.
In the in vivo model, the repeated administration of
dizocilpine lead to the expected prolongation of immobility
in the mice tested. It should be noted that the reactivity of
the mice cannot be correlated to an acute drug-effect of
dizocilpine, which is known to induce hyperactivity if
Toﬁsopam reduces negative symptoms of psychosis 1323
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after the last dose and in view of the half-life of dizocilpine
in rodents in the range of 2 h (Vezzani et al. 1989), the
behavioral modiﬁcation of the mice may rather be corre-
lated to a chronic plasticity. Our data indicate that the
model initially described using phencyclidine can be gen-
erated using dizocilpine instead (Noda et al. 1995).
Toﬁsopam, administered twice daily to the mice, was
capable of reducing the increased immobility in our model.
The effect was evident 3 days after the last dose of tof-
isopam, indicating that the effect cannot be related to an
acute effect of toﬁsopam on mouse behavior. The
enhancement of immobility induced by subchronic
administration of NMDA antagonists is attenuated by
clozapine and risperidone, which are known to improve
negative symptoms in patients, but not by haloperidol,
which does not improve them (Noda et al. 1995, 2000).
Toﬁsopam thus bears the potential to ameliorate negative
symptoms of psychosis such as avolition; however, no
complete normalization could be obtained. This may be
related to the short half-life of toﬁsopam in rodents, but
further experiments are needed to evaluate the potential of
toﬁsopam or other (more potent) 2,3-BZDs in psychosis.
Other models of negative symptoms of psychosis should be
also employed to evaluate whether negative symptoms
beyond avolition are also modiﬁed.
It may be discussed which phosphodiesterase isoen-
zymes may be responsible for the observed pharmacolog-
ical action in mice. Both, PDE-4 and PDE-10 isoenzymes
are involved in pharmacological action which may result in
effects on negative symptoms of psychosis. Siuciak
reviewed in 2008 the role of phosphodiesterases in psy-
chosis and she concludes that both isoenzymes bear great
potential for the treatment of positive symptoms, negative
symptoms and/or cognitive deﬁcits associated with
schizophrenia (Siuciak 2008). Drugs targeting both targets
may be of even higher interest. While the potential of such
dual inhibitors has not yet been explored systematically
and while no CNS-active drugs with selectivity for PDE-4
or PDE-10 are marketed so far, the availability of toﬁso-
pam enables a ﬁrst insight in the potential of such dual
inhibitors. Furthermore, the additional inhibition of PDE-2
may also contribute to the overall activity, adding anxio-
lytic effects and potentially also positive effects on cog-
nitive function. Toﬁsopam is not afﬂicted with the
well-known side effects of selective PDE-4 inhibitors. While
Bernard et al. (2008) discuss that toﬁsopam may represent
a novel structural class of tolerated PDE-4 inhibitors
without emetogenic potential, an alternative explanation to
the good tolerability may be that the combination of a
partial block of multiple PDEs with additive or even syn-
ergistic pharmacological effects results in the observed
pharmacology, while preventing the toxicity known from
highly selective and potent compounds, dosed to induce a
complete block of individual enzymes.
Other 2,3-BZDs may be systematically evaluated for
their interaction with PDE isoenzymes and compounds
with combined afﬁnity to PDE-4 and PDE-10, but also to
PDE-2 may be tested in respective animal models, with
focus on dual or even triple inhibitors.
Acknowledgments The authors wish to thank EGIS Pharmaceuti-
cals PLC (Budapest, Hungary) for a generous gift of toﬁsopam.
Conﬂict of interest The authors declare they have no conﬂict of
interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
Abdel-Naby SM, Noda Y, Mahmoud HM, Mamiya T, Nagai T,
Furukawa H, Nabeshima T (2001) Enhancement of immobility
induced by repeated phencyclidine injection: association with c-
Fos protein in the mouse brain. Behav Brain Res 124:71–76
Andra ´si F, Horva ´th K, Sineger E, Berzsenyi P, Borsy J, Kenessey A,
Tarr M, La ´ng T, K} oro ¨si J, Ha ´mori T (1987) Neuropharmacology
of a new psychotropic 2,3-benzodiazepine. Arzneimittelfors-
chung 37:1119–1124
Arnt J, Skarsfeldt T (1998) Do novel antipsychotics have similar
pharmacological characteristics? A review of the evidence.
Neuropsychopharmacology 18:63–101
BernardP,Dufresne-FavettaC,FavettaP,DoQT,HimbertF,Zubrzycki
S, Scior T, Lugnier C (2008) Application of drug repositioning
strategy to TOFISOPAM. Curr Med Chem 15:3196–3203
Bethke TD, Bohmer GM, Hermann R, Hauns B, Fux R, Morike K,
David M, Knoerzer D, Wurst W, Gleiter CH (2007) Dose-
proportional intraindividual single- and repeated-dose pharma-
cokinetics of roﬂumilast, an oral, once-daily phosphodiesterase 4
inhibitor. J Clin Pharmacol 47:26–36
Boess FG, Hendrix M, van der Staay FJ, Erb C, Schreiber R, van
Staveren W, de Vente J, Prickaerts J, Blokland A, Koenig G
(2004) Inhibition of phosphodiesterase 2 increases neuronal
cGMP, synaptic plasticity and memory performance. Neuro-
pharmacology 47:1081–1092
Domek-Łopacin ´ska K, Strosznajder JB (2008) The effect of selective
inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and
5 on learning and memory processes and nitric oxide synthase
activity in brain during aging. Brain Res 1216:68–77
Field SK (2008) Roﬂumilast: an oral, once-daily selective PDE-4
inhibitor for the management of COPD and asthma. Expert Opin
Investig Drugs 17:811–818
Goenen M (1989) Historical perspectives and update of amrinone.
J Cardiothorac Anesth 3:15–23
Horva ´th K, Andra ´si F, Berzsenyi P, Pa ´tfalusi M, Patthy M, Szabo ´ G,
Sebestye ´n L, Bagdy E, K} oro ¨si J, Botka P, Ha ´mori T, La ´ng T
(1989) A new psychoactive 5H-2,3-benzodiazepine with a
unique spectrum of activity. Arzneimittelforschung 39:894–899
Horva ´th EJ, Palkovits M, Lenkei Z, Gyu ¨re KI, Fekete MI, Ara ´nyi P
(1994) Autoradiographic localization and quantitative determi-
nation of speciﬁc binding sites of anxiolytic homophthalazines
1324 C. Rundfeldt et al.
123(formerly called 2,3-benzodiazepines) in the striato-pallido-
nigral system of rats. Brain Res Mol Brain Res 22:211–218
Horva ´th EJ, Horva ´th K, Ha ´mori T, Fekete MI, So ´lyom S, Palkovits M
(2000) Anxiolytic 2,3-benzodiazepines, their speciﬁc binding to
the basal ganglia. Prog Neurobiol 60:309–342
Kanes SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T, Kelly MP (2007)
Rolipram: a speciﬁc phosphodiesterase 4 inhibitor with potential
antipsychotic activity. Neuroscience 144:239–246
Klebovich I, Abermann M (1993) Pharmacokinetics and metabolism
of toﬁzopam (Grandaxin). Acta Pharm Hung 63:83–90
La ´ng T, K} oro ¨si J, Zo ´lyomi G, Ha ´mori T, Botka P (1985) Design and
synthesis of 5H-2,3-benzodiazepines. In: Vizi ES, Furst S, Zsilla
G (eds) Proc. 4th Cong. Hung. Pharmacol. Soc., Pergamon Press
and Publishing House of the Hungarian Academy of Sciences,
Oxford and Budapest, pp 91–97
MacKenzie S, Hastings S, Wells C (2010) Cyclic nucleotide
phosphodiesterase assay technology. Curr Protoc Pharmacol
49:3.12.1–3.12.26
Masood A, Huang Y, Hajjhussein H, Xiao L, Li H, Wang W, Hamza
A, Zhan CG, O’Donnell JM (2009) Anxiolytic effects of
phosphodiesterase-2 inhibitors associated with increased cGMP
signaling. J Pharmacol Exp Ther 331:690–699
Nielsen EB, Kehler J, Nielsen J, Brøsen P (2007) Patent: use of
toﬁsopam as a PDE10A inhibitor. WO 2007/082546 A1
Noda Y, Yamada K, Furukawa H, Nabeshima T (1995) Enhancement
of immobility in a forced swimming test by subacute or repeated
treatment with phencyclidine: a new model of schizophrenia. Br
J Pharmacol 116:2531–2537
Noda Y, Kamei H, Mamiya T, Furukawa H, Nabeshima T (2000)
Repeated phencyclidine treatment induces negative symptom-
like behavior in forced swimming test in mice: imbalance of
prefrontal serotonergic and dopaminergic functions. Neuropsy-
chopharmacology 23:375–387
Petocz L (1993) Pharmacologic effects of toﬁzopam (Grandaxin).
Acta Pharm Hung 63:79–82
Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms
JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, Proulx-
LaFrance C, Majchrzak MJ, Ramirez AD, Schmidt K, Seymour
PA, Siuciak JA, Tingley FD III, Williams RD, Verhoest PR,
Menniti FS (2008) Preclinical characterization of selective
phosphodiesterase 10A inhibitors: a new therapeutic approach
to the treatment of schizophrenia. J Pharmacol Exp Ther
325:681–690
Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL,
Lanfear J, Ryan AM, Schmidt CJ, Strick CA, Varghese AH,
Williams RD, Wylie PG, Menniti FS (2003) Immunohistochem-
ical localization of PDE10A in the rat brain. Brain Res
985:113–126
Siuciak JA (2008) The role of phosphodiesterases in schizophrenia:
therapeutic implications. CNS Drugs 22:983–993
Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA,
Chambers L, Shrikhande A, Wong S, Menniti FS, Schmidt CJ
(2006) Inhibition of the striatum-enriched phosphodiesterase
PDE10A: a novel approach to the treatment of psychosis.
Neuropharmacology 51:386–396
Szeg} o J, Somogyi M, Papp E (1993) Excerpts from the clinical-
pharmacologic and clinical studies of Grandaxin. Acta Pharm
Hung 63:91–98
To ´th M, Bereczki A, Drabant S, Nemes KB, Varga B, Gre ´zal G,
To ¨ml} o J, Lakner G, Klebovich I (2006) Gas chromatography
nitrogen phosphorous detection (GC-NPD) assay of toﬁsopam in
human plasma for pharmacokinetic evaluation. J Pharm Biomed
Anal 41:1354–1359
Verhoest PR, Chapin DS, Corman M, Fonseca K, Harms JF, Hou X,
Marr ES, Menniti FS, Nelson F, O’Connor R, Pandit J, Proulx-
LaFrance C, Schmidt AW, Schmidt CJ, Suiciak JA, Liras S
(2009) Discovery of a novel class of phosphodiesterase 10A
inhibitors and identiﬁcation of clinical candidate 2-[4-(1-methyl-
4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-
2545920) for the treatment of schizophrenia. J Med Chem
52:5188–5196
Vezzani A, Seraﬁni R, Stasi MA, Caccia S, Conti I, Tridico RV,
Samanin R (1989) Kinetics of MK-801 and its effect on
quinolinic acid-induced seizures and neurotoxicity in rats.
J Pharmacol Exp Ther 249:278–283
Toﬁsopam reduces negative symptoms of psychosis 1325
123